What We're Reading: Page 2
Industry reads hand-picked by our editors
May 08, 2024
May 07, 2024
May 06, 2024
-
FirstWord Pharma
Pfizer taps Citi analyst Andrew Baum as strategy chief
-
Fierce Biotech
GlycoMimetics fails phase 3 blood cancer trial, sinking stock
-
Politico
‘They need to back off’: Farm states push back on Biden’s bird flu response
-
The Wall Street Journal
‘Green Shoots’ Grow Out of Control on Wall Street
May 03, 2024
-
Fierce Pharma
WuXi Biologics withdraws from 2024 BIO convention amid worsening geopolitical tensions
-
NPR
Could the U.S. produce an effective bird flu vaccine for humans, if needed?
-
Healthcare Dive
Walgreens inks GLP-1 clinical trial deal with major German drugmaker
-
JAMA
The FDA and Gene Therapy for Duchenne Muscular Dystrophy
May 02, 2024
May 01, 2024
Apr 30, 2024
-
STAT
Federal judge rules against two drugmakers challenging Medicare drug price negotiation program
-
Fierce Biotech
Novartis pays PeptiDream $180M as radiopharma big bang continues
-
The Boston Globe
FDA approves X4 Pharmaceuticals’ drug for ultra-rare WHIM syndrome
-
The Pharma Letter
Amgen deal frees Sandoz to launch Prolia and Xgeva biosimilars next year